Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
Table of Contents

The number of shares of common stock shown as issued and outstanding in the table excludes:
 
  •      2,297,062 shares of common stock issuable upon the exercise of options outstanding as of December 31, 2006 at a weighted average exercise price of $1.24 per share and 55,000 shares of common stock issuable upon the exercise of options granted during February 2007 at an exercise price of $10.72 per share; and
 
  •      4,228,240 shares of our common stock reserved for future issuance under our 2007 equity incentive award plan, which will become effective on the day prior to the day on which we become subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act (including 703,240 shares of common stock reserved for future grant or issuance under our 2004 stock plan, which shares will be added to the shares to be reserved under our 2007 equity incentive award plan upon the effectiveness of the 2007 equity incentive award plan).
 
The cash and cash equivalents and investment securities, available-for-sale shown in the table do not include $10.0 million borrowed in March 2007 under our credit and security agreement entered into with Merrill Lynch Capital in December 2006. An additional $7.0 million is available for future borrowings under the terms of, and subject to the conditions in, the credit and security agreement. See Note 3 of Notes to Financial Statements.


43